Global CDMOs Rentschler Biopharma and Vetter have announced Xpert Alliance, a joint visualisation of their strategic collaboration. According to the companies, the visualisation is designed to “bring to life” the ongoing alliance in the area of complex biopharmaceuticals.
In mid-2020, the companies entered a strategic alliance with the goal of helping clients bring complex products to patients faster and more easily, through the coordination of their respective manufacturing services. By offering complementary strengths along the biopharmaceutical value chain, they say, the CDMOs have mutually enhanced their services. Today’s announcement is said to mark an important step in heightening the visibility of these collaborative services to clients.
“It is exciting to see how our alliance has been steadily evolving and taking shape,” said Dr. Frank Mathias, CEO of Rentschler Biopharma. “We and Vetter have ambitious goals for our collaboration and believe that our clients can greatly benefit from the complementary services and seamless interactions we offer, with the ultimate aim of bringing new, life-changing treatment options to patients.”
Vetter MD Peter Soelkner said: “With joint projects ongoing, the day-to-day workings of our strategic alliance are running smoothly, as we work together to create best-in-class solutions for our clients from early development stage through to the market. We are pleased with the progress we have made so far and look forward to demonstrating the added value we are generating through our collaboration.”
